Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.

Royalty Pharma's Q3 results show growth driven by strong portfolio performance and acquisitions. See why we recommend a buy ...

A new focus on dermatology, ophthalmology, and gastroenterology will pave ways for many untapped opportunities that Viatris can utilize with its scale and manufacturing power. We believe Viatris is in ...

Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.

Q3 2024 Earnings Call Transcript November 6, 2024 Royalty Pharma plc misses on earnings expectations. Reported EPS is $0.918 ...

Plus: How AI can help cancer patients avoid unnecessary chemotherapies and make it easier to understand your dental X-rays.

Portfolio Receipts growth of 15% to $735 million; Royalty Receipts growth of 15%Net cash provided by operating activities of $704 millionCapital Deployment of approximately $1.2 billion Raising full ...

Novo Nordisk (NVO), the maker of blockbuster weight-loss and diabetes drugs Wegovy and Ozempic, has entered an agreement with Denmark-based Ascendis Pharma (ASND) to leverage the latter’s advanced ...

In a deal worth up to $285 million initially for the lead program, Novo Nordisk will gain access to Ascendis’ TransCon ...

Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.

Leerink Partners analyst Joseph Schwartz maintained a Buy rating on Ascendis Pharma (NASDAQ:ASND) on Wednesday, setting a price target of $178, which is approximately ...

BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong ...